PE20070360A1 - Composiciones de liposomas - Google Patents

Composiciones de liposomas

Info

Publication number
PE20070360A1
PE20070360A1 PE2006001052A PE2006001052A PE20070360A1 PE 20070360 A1 PE20070360 A1 PE 20070360A1 PE 2006001052 A PE2006001052 A PE 2006001052A PE 2006001052 A PE2006001052 A PE 2006001052A PE 20070360 A1 PE20070360 A1 PE 20070360A1
Authority
PE
Peru
Prior art keywords
liposomes
therapeutic agent
liposome compositions
composition
cations
Prior art date
Application number
PE2006001052A
Other languages
English (en)
Inventor
Saran Kumar
Wenlei Jiang
Jia-Ai Zhang
Jorg Ogorka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37715942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070360A1 publication Critical patent/PE20070360A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIPOSOMAS QUE COMPRENDE UNA MATRIZ DE CATIONES DIVALENTES TALES COMO IONES DE CAlCIO O CATIONES DE ZINC O MAGNESIO, LA CUAL CONTIENE UN AGENTE TERAPEUTICO DE FORMULA I, DONDE R1 ES HETEROCICLO DE 5 MIEMBROS, QUE CONTIENE COMO HETEROATOMOS DE N, O, S, Y EL CUAL ESTA SUSTITUIDO POR ALQUILO INFERIOR, FENILO, ENTRE OTROS. DICHO AGENTE TERAPEUTICO ES DE PREFERENCIA ACIDO ZOLEDRONICO. LA COMPOSICION DE LIPOSOMAS TIENE UN TAMANO DE PARTICULA PROMEDIO DE APROXIMADAMENTE 10-500 NANOMETROS Y COMPRENDE ADEMAS UN LIGANDO EFECTIVO PARA ENLAZARSE ESPECIFICAMENTE A UN ANTIGENO ESPECIFICO DEL TUMOR
PE2006001052A 2005-09-01 2006-08-29 Composiciones de liposomas PE20070360A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71327305P 2005-09-01 2005-09-01

Publications (1)

Publication Number Publication Date
PE20070360A1 true PE20070360A1 (es) 2007-04-19

Family

ID=37715942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001052A PE20070360A1 (es) 2005-09-01 2006-08-29 Composiciones de liposomas

Country Status (14)

Country Link
US (1) US20080286352A1 (es)
EP (1) EP1924247A2 (es)
JP (1) JP2009507029A (es)
KR (1) KR20080038379A (es)
CN (1) CN101252912A (es)
AR (1) AR055621A1 (es)
AU (1) AU2006284642A1 (es)
BR (1) BRPI0616598A2 (es)
CA (1) CA2620400A1 (es)
GT (1) GT200600391A (es)
PE (1) PE20070360A1 (es)
RU (1) RU2008111967A (es)
TW (1) TW200744669A (es)
WO (1) WO2007028020A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
EP2440250A1 (en) * 2009-06-11 2012-04-18 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011038073A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术（石家庄）有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
ITNA20100046A1 (it) * 2010-09-28 2012-03-29 Abbruzzese Saccardi Alberto Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico
IT1401882B1 (it) * 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
EP2823811A1 (en) 2013-07-09 2015-01-14 OTC GmbH Targeted active release system comprising solid lipid nano-particles
AU2013401479B2 (en) * 2013-09-26 2019-04-04 BioNTech SE Particles comprising a shell with RNA
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ANY COMBINATION THEREOF
BR112019022423A2 (pt) * 2017-04-28 2020-09-01 Texas Children's Hospital composto ou um agente que alveja integrina, composição, e, métodos para produzir um lipossomo, para produzir um agente que alveja integrina, para liberação de fármaco, para obter imagens, para liberar um agente bioativo, para obter imagem de uma estrutura biológica e para identificar um paciente em risco
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
WO2020207472A1 (zh) * 2019-04-11 2020-10-15 厦门万泰沧海生物技术有限公司 唑来膦酸锌微纳米颗粒佐剂的制备及作为疫苗佐剂的用途
TWI763991B (zh) * 2019-05-02 2022-05-11 行政院原子能委員會核能研究所 新式眼用凝膠及其製備方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
NZ335676A (en) * 1997-09-09 2001-03-30 Select Release L Coated particles comprising an exterior coating and a matrix comprising a liquid phase or liquid crystalline phase which is nanostructured
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
US7090865B2 (en) * 2001-11-29 2006-08-15 National Jewish Medical And Research Center Composition and method for treating autoimmune hemolytic anemia
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample

Also Published As

Publication number Publication date
TW200744669A (en) 2007-12-16
AU2006284642A1 (en) 2007-03-08
WO2007028020A3 (en) 2007-05-31
AR055621A1 (es) 2007-08-29
BRPI0616598A2 (pt) 2011-06-28
EP1924247A2 (en) 2008-05-28
JP2009507029A (ja) 2009-02-19
CA2620400A1 (en) 2007-03-08
US20080286352A1 (en) 2008-11-20
RU2008111967A (ru) 2009-10-10
KR20080038379A (ko) 2008-05-06
CN101252912A (zh) 2008-08-27
WO2007028020A2 (en) 2007-03-08
GT200600391A (es) 2007-04-02

Similar Documents

Publication Publication Date Title
PE20070360A1 (es) Composiciones de liposomas
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
EA201290919A1 (ru) Индазольные соединения и их применение
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
UY29902A1 (es) Diarilureas para el tratamiento de la hipertensión pulmonar
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
HN2010000674A (es) Composicion y metodos de uso para anticuerpos contra la esclerostina
EA201001639A1 (ru) Композиции и способы их получения и применения
UY31992A (es) Formas sólidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol y métodos para su uso
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA201171284A1 (ru) Новая технология изготовления напроксена
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
EP3000885A3 (en) Organic compositions to treat hsf1-related diseases
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
BR112012026659A2 (pt) composto para desinfecção de superfícies.
UY30675A1 (es) Metodos para el tratamiento de la depresion
PE20061245A1 (es) Composiciones para la transmision transmucosa oral de la metformina
BR112013017267A8 (pt) formulação de lipossomas, suspensão e composição farmacêutica
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
CL2008003933A1 (es) Compuestos derivados de n-heterociclo-[1,2-a]-piridina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.

Legal Events

Date Code Title Description
FD Application declared void or lapsed